Advertisement

Topics

IntelGenx to Report Second Quarter 2017 Financial Results on August 10, 2017 - Conference Call to Follow

20:00 EDT 2 Aug 2017 | Marketwired

SAINT-LAURENT, QUEBEC -- (Marketwired) -- 08/03/17 -- IntelGenx Technologies Corp., (TSX VENTURE: IGX)(OTCQX: IGXT), today announced that it will release its second quarter 2017 financial results after market close on August 10, 2017.

An accompanying conference call will be hosted by Dr. Horst G. Zerbe, President and Chief Executive Officer, and Mr. Andre Godin, Executive Vice-President and Chief Financial Officer, to discuss the results and provide a business update. Details of the conference call and webcast are below:

Webcast Registration: Click here

Following the live call, a replay will be available on the Company's website, www.intelgenx.com, under "Investor Relations".

About IntelGenx:

Established in 2003, IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform.

IntelGenx' highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx' state-of-the-art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to its clients. More information about the company can be found at www.intelgenx.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange), nor the OTCQX accepts responsibility for the adequacy or accuracy of this release.

Source: IntelGenx Technologies Corp.

Contacts: IntelGenx Technologies Corp. Stephen Kilmer Investor Relations (514) 331-7440 ext 232 IntelGenx Technologies Corp. Andre Godin, CPA, CA Executive Vice-President and CFO (514) 331-7440 ext 203 NEXT ARTICLE

More From BioPortfolio on "IntelGenx to Report Second Quarter 2017 Financial Results on August 10, 2017 - Conference Call to Follow "

Quick Search
Advertisement
 

Relevant Topics

Drug Delivery
<!--LGfEGNT2Lhm-->Drug delivery is the method or process of administering a pharmaceutical compound to achieve a therapeutic effect in humans or animals.  <!--LGfEGNT2Lhm-->Drug delivery technologies are <!--LGfEGNT2Lhm-->patent pr...

Antiretroviral therapy
Standard antiretroviral therapy (ART) consists of the combination of at least three antiretroviral (ARV) drugs to maximally suppress the HIV virus and stop the progression of HIV disease. Huge reductions have been seen in rates of death and suffering whe...